Lee, C M <br/><br/>
VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.  [electronic resource] 

 -  Oncogene  Apr 2009 
 - 1694-705 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5594 
<br/><br/><label>Standard No.: </label>10.1038/onc.2009.12  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Basic Helix-Loop-Helix Transcription Factors--physiology<br/>Cell Line<br/>Female<br/>Humans<br/>Hypoxia-Inducible Factor 1, alpha Subunit--physiology<br/>Kidney Neoplasms--etiology<br/>Mice<br/>Mice, Inbred C57BL<br/>Mutation<br/>Teratoma--blood supply<br/>Von Hippel-Lindau Tumor Suppressor Protein--genetics